Eton Pharmaceuticals (NASDAQ:ETON) Announces Quarterly Earnings Results

Eton Pharmaceuticals (NASDAQ:ETON) issued its quarterly earnings results on Thursday. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.28, FiscalAI reports. The company had revenue of $37.59 million for the quarter, compared to analyst estimates of $27.11 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%.

Here are the key takeaways from Eton Pharmaceuticals’ conference call:

• Record Q2 performance — Revenue rose 99% year over year to $37.6 million, adjusted EBITDA increased to $16.2 million, and net income reached $11.6 million versus a prior-year loss.
• Eton raised its 2026 outlook, now expecting revenue above $145 million versus prior guidance of more than $120 million, while increasing its adjusted EBITDA margin forecast to above 35% from above 30%.
• HEMANGEOL’s relaunch exceeded expectations, with approximately 95% of patients transitioned to Eton Cares by the end of June; management sees further growth from converting patients using off-label treatments and expects annual patients to exceed 10,000.
• The company added ASN-001, a late-stage topical hemangioma treatment that could address a larger patient population than HEMANGEOL and use the same commercial infrastructure. Eton plans to begin a $4 million bioavailability study shortly, submit an NDA in the second half of 2027, and potentially launch in 2028.
• Eton also advanced KHINDIVI, INCRELEX, Amglidia, DESMODA, Galzin, and ET-700, while adding U.S. rights to IMPAVIDO; however, several opportunities remain dependent on clinical studies, regulatory approvals, or future commercialization efforts.

Eton Pharmaceuticals Trading Down 1.9%

Shares of NASDAQ:ETON opened at $40.80 on Friday. Eton Pharmaceuticals has a 52 week low of $14.27 and a 52 week high of $50.18. The company’s 50 day moving average is $38.47 and its two-hundred day moving average is $28.38. The company has a market cap of $1.12 billion, a PE ratio of -582.77 and a beta of 0.86. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. HC Wainwright boosted their price target on shares of Eton Pharmaceuticals from $57.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday. Craig Hallum upped their price objective on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Canaccord Genuity Group initiated coverage on Eton Pharmaceuticals in a research note on Thursday, July 16th. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, Zacks Research lowered Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Eton Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $54.50.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, Director Jennifer Mckie Adams sold 50,000 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total value of $1,624,000.00. Following the sale, the director directly owned 50,000 shares in the company, valued at $1,624,000. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Krempa sold 42,797 shares of Eton Pharmaceuticals stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $33.39, for a total value of $1,428,991.83. Following the sale, the insider directly owned 25,249 shares of the company’s stock, valued at $843,064.11. This trade represents a 62.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 150,000 shares of company stock valued at $4,853,921. Insiders own 16.49% of the company’s stock.

Institutional Investors Weigh In On Eton Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quarry LP purchased a new stake in Eton Pharmaceuticals during the third quarter worth approximately $37,000. Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $44,000. Legal & General Group Plc purchased a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $41,000. New York State Common Retirement Fund purchased a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $115,000. Finally, State of Wyoming boosted its holdings in shares of Eton Pharmaceuticals by 50.0% in the 4th quarter. State of Wyoming now owns 8,161 shares of the company’s stock valued at $138,000 after buying an additional 2,721 shares in the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals News Summary

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: The earnings call and quarterly release give investors additional detail on Eton’s operating performance and commercialization progress following the sizable earnings and revenue beats. Eton Pharmaceuticals Q2 2026 Earnings Call Transcript
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $65 price target, above the recent trading range, indicating that the analyst remains constructive despite reducing its longer-term earnings forecasts. HC Wainwright Issues Negative Outlook for ETON Earnings
• Negative Sentiment: HC Wainwright lowered its EPS estimates for fiscal 2027 through 2030 to $1.28, $2.23, $4.25 and $6.53, respectively, from $1.83, $3.50, $5.85 and $8.65. These cuts signal reduced expectations for Eton’s longer-term earnings growth and may limit the positive impact of the quarterly beat.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.